Buprenorphine ‘Underused’ in Primary Care as Opioid Abuse Soars

Source : http://www.medscape.com/viewarticle/863638

The DATA waiver is not required to prescribe buprenorphine for pain — it is needed only for addiction, Dr Grande said. « But insurance will usually not pay for the drug when it’s prescribed for pain. This is because of a technicality. Prescribing the high-dose sublingual form — which is FDA [Food and Drug Administration]-approved to treat addiction — is not FDA-approved to treat pain. »

The certification, which involves just 8 hours of training, provides very helpful information on legal issues and pharmacology the drug, she said.

With a pressing need for more physicians with the DATA waivers, Dr Grande expressed the hope that the waivers to prescribe buprenorphine for addiction will at some point extend beyond physicians.

« Availability to patients would be much better if nurse practitioners and physician assistants were able to prescribe the drug, » she asserted. « But this will literally take an act of Congress. » The rules were set by DATA, which was a congressional act.

Though an opioid itself, buprenorphine, a partial agonist, has a high binding affinity at the μ-opioid receptors, allowing the drug to counter the effects of full agonist opioids, such as morphine, blocking the euphoria and having a significantly lower risk for respiratory depression or overdose.

« Buprenorphine wipes out withdrawal and craving, it reverses sedation and actually turns it into activation, making people want to get out and become active, » Dr Grande explained.

« The transformation you see in patients with this is unbelievable. »

Among the 70 patients that Dr Grande said she has on buprenorphine, approximately half are primarily being treated for addiction and the other half, for pain, but there is overlap, with some patients being treated for both.

Patients who are ideal candidates for buprenorphine include those being treated with long-term opiates who are showing the red flags of problematic behavior and possible addiction.

« When they come to you for that next early refill — because it is the early refills that indicate a problem, you tell them you can’t, but you say ‘what I can do is offer you this other medicine that I think will really do a better job for you in the long run.' »

« I don’t push it but will raise the issue and when they do accept it, patients are almost always happy with the change. »

Jonathan Daitch, MD, medical director of Advanced Pain Management & Spine Specialists, in Fort Myers, Florida, who also spoke on the issue during the symposium here, noted that when his patients show signs of opioid overuse and resist the switch to buprenorphine, he doesn’t give them a choice if they want to continue treatment at his practice.

« At some point we have a behaviour discussion and I have to tell them I can’t tolerate this behavior. If you want me to continue to treat you, you either have to convert to this safer drug or find another doctor. »

Dr Daitch added that patients need to be educated about the spectrum of symptoms that are more the result of opioid overuse than the chronic pain that the opioids are being used to treat. He highlighted hyperalgesia, which he described as an increased sensitivity to pain that is typical in patients on high-dose opioids.

Dr Daitch said he had converted about 1000 patients from traditional opioids to buprenorphine. « The key to converting patients to buprenorphine is to educate them that they are treating withdrawal and not pain. » He said he doesn’t need to use his DATA waiver because he is actually treating pain. Most of these patients do not have a true addiction.

« They need to know that much of what they are feeling is not pain but a drug-induced withdrawal syndrome, and if the circular behavior of the opioid overuse can be broken, their pain would be significantly improved. »

« You have to be careful transitioning patients from methadone. You have to wait 5 half-lives for the opioid to be eliminated from the body, » he said.

« I like to put them on oxycodone for 5 days to make an easy transition to buprenorphine. »

Dr Daitch noted that buprenorphine’s analgesic effect increases over the first week of treatment. « The brain needs time to reset its pain sensitivity perception and threshold, » he said.

« Pain and withdrawal symptoms decrease as the week continues, and those who really want to get better tend to do just fine. »

Voir aussi

Feu vert pour les centres d’injection supervisée en Alberta

Source : http://ici.radio-canada.ca/nouvelle/1062184/centres-injection-supervisee-edmonton-lethbridge Le gouvernement de l’Alberta a annoncé mercredi l’approbation du fédéral pour quatre ...

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *